Synonyms: Example 47 [WO2014184275A1] | Example XLVII [WO2014184275A1] | LY-3556050 | mazisotine
Compound class:
Synthetic organic
Comment: LY3556050 is a non-peptide somatostatin receptor subtype 4 (SST4) receptor agonist [1].
SST4 is expressed by peripheral sensory neurons and SST4-mediated antinociception is being pursued as a promising mechanism for non-opioid pain relief. ![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
LY3556050 is a clinical candidate. It is being investigated for analgesic potential. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT06074562 | A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain | Phase 2 Interventional | Eli Lilly and Company | ||
NCT05986292 | A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain | Phase 2 Interventional | Eli Lilly and Company | ||
NCT04627038 | Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis | Phase 2 Interventional | Eli Lilly and Company | ||
NCT04874636 | Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Chronic Low Back Pain | Phase 2 Interventional | Eli Lilly and Company |